Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.
Saved in:
| Title: | Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup. |
|---|---|
| Authors: | Okada AA; Department of Ophthalmology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo, 181-8611, Japan. aokada@e23.jp., Takahashi K; Department of Ophthalmology, Kansai Medical University, Osaka, Japan., Ohji M; Department of Ophthalmology, Shiga University of Medical Science, Otsu, Shiga, Japan., Moon SC; Department of Medical Affairs and Pharmacovigilance, Bayer AG, Berlin, Germany., Machewitz T; Department of Research and Development, Bayer AG, Berlin, Germany., Sasaki K; Department of Medical Affairs and Pharmacovigilance, Bayer Yakuhin Ltd., Osaka, Japan. |
| Corporate Authors: | ALTAIR Study Investigators |
| Source: | Advances in therapy [Adv Ther] 2022 Jun; Vol. 39 (6), pp. 2984-2998. Date of Electronic Publication: 2022 May 03. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1865-8652 |
|---|---|
| DOI: | 10.1007/s12325-022-02162-w |
